Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Prisons as HIV prevention hubs: can opioid treatment reach more people behind bars?

NCT ID NCT06962033

Prevention Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers at Yale University are studying how to expand opioid agonist therapy (OAT) in prisons and probation systems in Tajikistan, Kyrgyzstan, Moldova, and Georgia. OAT uses medicines like methadone or buprenorphine to treat opioid dependence and can lower HIV transmission among people who inject drugs. The study enrolls about 300 prison and probation staff and people on probation. It identifies barriers to OAT scale-up and tests a learning collaborative called NIATx to help sites increase the number of people receiving OAT.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Opioid agonist therapy, a treatment that uses medicines like methadone or buprenorphine to reduce opioid cravings and withdrawal
What this could lead to
If the learning collaborative helps prisons and probation services expand opioid agonist therapy, it could reduce HIV transmission among people who inject drugs in Tajikistan, Kyrgyzstan, Moldova, and Georgia.
What could go wrong
This is an observational scale-up study, not a randomized trial, so it cannot prove that the collaborative causes any increase in treatment. Prisons and probation services may face barriers that the collaborative cannot overcome, and results in these four countries may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Aim 1: 1. Quantitative surveys for prison OAT providers * Being 18 years or older * Being currently assigned and working as a probation OAT provider for a probation site 2. ECHO procedures Aim 2: 1. Quantitative surveys for people in probation * Being 18 years or older * Screen yes to opioid injection on the online screener questionnaire * Currently in probation 2. Quantitative surveys for probation and prison officers * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation site 3. Focus Groups (People in probation) * Being 18 years or older * Screen yes to opioid injection criteria on the online screener * Currently in probation 4. Focus Groups (Probation and prison officers) * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation * Has more than 3 months of field experience * Works at a probation site within 25 kilometers of an OAT site Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV Opioid use

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AIDS Foundation East-West (AFEW)

    RECRUITING

    Bishkek, Kyrgyzstan

  • Alternative Georgia

    RECRUITING

    Tbilisi, Georgia

  • Institute for International Health and Education (IIHE)

    RECRUITING

    Dushanbe, Tajikistan

  • NGO AFI

    RECRUITING

    Chisinau, Moldova

  • Yale University

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.